Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025-Reference-Cited by-同舟云学术

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025

Published:2017-09 Issue:3 Volume:72 Page:368-376
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Escudier Bernard,Motzer Robert J.,Sharma Padmanee,Wagstaff John,Plimack Elizabeth R.,Hammers Hans J.,Donskov Frede,Gurney Howard,Sosman Jeffrey A.,Zalewski Pawel G.,Harmenberg Ulrika,McDermott David F.,Choueiri Toni K.,Richardet Martin,Tomita Yoshihiko,Ravaud Alain,Doan Justin,Zhao Huanyu,Hardy Helene,George Saby

Publisher

Elsevier BV

Subject

Urology

Reference21 articles.

1. Radiologic heterogeneity in responses to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma;de Velasco;Cancer Immunol Res,2016

2. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE);Grothey;J Clin Oncol,2008

3. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: patterns of disease progression and clinical management of limited progression;Puzanov;Eur J Cancer,2015

4. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study;von Minckwitz;J Clin Oncol,2009

5. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria;Wolchok;Clin Cancer Res,2009

Cited by 205 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study;Neoplasia;2024-11

2. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy;Molecular Cancer;2024-09-02

3. The efficacy of subsequent therapy after failure of anti-PD-1 antibody in metastatic renal cell carcinoma;Translational Cancer Research;2024-05

4. Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study;Frontiers in Oncology;2024-02-12

5. 15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis;eClinicalMedicine;2024-02